Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Selective oestrogen receptor modulator for osteoporosis in postmenopausal women. | Hormone therapy that has saved hundreds of thousands from breast cancer. |
| Body system | Cancer | Cancer |
| Drug class | Selective oestrogen receptor modulators | Selective oestrogen receptor modulators |
| Supply | Prescription only | Prescription onlyWHO essential medicine |
| Main uses | Osteoporosis after menopause, Reducing breast cancer risk in high-risk women | Hormone-receptor-positive breast cancer (pre- and post-menopause), Breast cancer prevention in high risk, Male breast cancer |
| How it works | Protects bones in the way oestrogen does, without stimulating the breast. | Stops oestrogen fuelling breast cancer cells. |
| Starts working | Months | — |
| Half-life | About 28 hours | 5–7 days |
| Typical adult dose | 60 mg once a day. | 20 mg once a day for 5–10 years. |
| Forms | Tablet | Tablet, Oral solution |
| Common side effects | Hot flushes, Leg cramps, Swelling, Flu-like symptoms | Hot flushes, Vaginal discharge, Irregular periods, Mood changes |
| Serious side effects | Blood clots in veins and lungs, Stroke death risk | Blood clots, Womb cancer (post-menopause), Stroke, Cataracts |
| Don't take if | History of blood clots; Unexplained uterine bleeding; Active liver disease; Pregnancy and breastfeeding | Pregnancy; History of blood clots (caution); Taking potent CYP2D6 inhibitors (paroxetine, fluoxetine) — reduces effect; Undiagnosed vaginal bleeding |
| Alcohol | Usually no problem in moderation. No specific interaction. | Usually no problem in moderation. No specific interaction. |
| Pregnancy | Usually avoidedContraindicated in pregnancy and in women who may become pregnant. | Usually avoidedCan harm the fetus; avoid pregnancy for 2 months after stopping. |
| Breastfeeding | Usually avoidedNot recommended. | Usually avoidedAvoid. |
| In use since | — | 1973 |
| Brand names | United States: EvistaUnited Kingdom: EvistaIndia: Evista, Raloxifene (generic) | United States: SoltamoxUnited Kingdom: Nolvadex-D, SoltamoxIndia: Tamodex, Mamofen |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H |
| ATC code | G03XC01 | L02BA01 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker